PMID: 2865745Sep 1, 1985Paper

Inhibition of thromboxane and prostacyclin production in whole blood by adrenoceptor antagonists

Prostaglandins, Leukotrienes, and Medicine
I A GreerC D Forbes

Abstract

There is increasing evidence implicating thromboxane A2 (TxA2) in vascular disease. Adrenergic blocking agents have been used with success in the secondary prevention of myocardial infarction. The aim of this study was to determine whether adrenergic blocking agents had any effect on the production of TxA2 and prostacyclin (PGI2) from whole blood in vitro. Fresh whole blood without anticoagulant was placed in glass tubes containing either drug or vehicle, the latter acting as control, and allowed to clot at 37 degrees C for 30 minutes. The serum PGI2 metabolites (PGI2M) and TxB2 (the stable hydration product of TxA2) were determined by radioimmunoassay. Labetalol, pindolol and propranolol all inhibited both PGI2M and TxB2 production in a dose dependent manner, while atenolol had no effect. Labetalol was the most potent significantly inhibiting TxB2 production at a drug concentration compatible with that found in-vivo. This inhibitory effect on TxB2 production may be of benefit in the treatment of vascular disease.

References

Apr 1, 1979·Prostaglandins and Medicine·R I LewyL Wiener
Jan 1, 1978·Prostaglandins·E Granström
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Mar 1, 1981·The Journal of Pharmacy and Pharmacology·P B Woods, M L Robinson
Oct 15, 1982·Thrombosis Research·D GreenO Haring
Mar 26, 1983·British Medical Journal·J FeelyD Maclean
Apr 30, 1983·British Medical Journal·C M Kaye
Jan 1, 1983·Toxicon : Official Journal of the International Society on Toxinology·G CanzianiJ C Vidal
Apr 2, 1981·The New England Journal of Medicine·UNKNOWN Norwegian Multicenter Study Group
Apr 23, 1981·The New England Journal of Medicine·R M RobertsonJ A Oates
May 20, 1999·Annual Review of Pharmacology and Toxicology·J BalsindeE A Dennis

❮ Previous
Next ❯

Citations

Apr 1, 1987·Prostaglandins, Leukotrienes, and Medicine·M Ali, M Afzal
Jul 1, 1989·Baillière's Clinical Haematology·J Vermylen, D Blockmans
Sep 19, 2006·Obstetrical & Gynecological Survey·Michael A BelfortBaha Sibai
Oct 17, 1998·Acta Anaesthesiologica Scandinavica·I PowerI A Greer
Jul 1, 1988·Prostaglandins, Leukotrienes, and Essential Fatty Acids·J PascualE S Borda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.